Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Testing the biosocial cognitive model of substance use in cannabis users referred to treatment.

Papinczak ZE, Connor JP, Feeney GFX, Harnett P, Young RM, Gullo MJ.

Drug Alcohol Depend. 2018 Nov 6;194:216-224. doi: 10.1016/j.drugalcdep.2018.09.032. [Epub ahead of print]

PMID:
30453107
2.

A randomized controlled trial and economic evaluation of the Parents Under Pressure program for parents in substance abuse treatment.

Barlow J, Sembi S, Parsons H, Kim S, Petrou S, Harnett P, Dawe S.

Drug Alcohol Depend. 2018 Nov 3;194:184-194. doi: 10.1016/j.drugalcdep.2018.08.044. [Epub ahead of print]

3.

A virtual clinic to improve long-term outcomes in chronic kidney disease.

Harnett P, Jones M, Almond M, Ballasubramaniam G, Kunnath V.

Clin Med (Lond). 2018 Oct;18(5):356-363. doi: 10.7861/clinmedicine.18-5-356.

PMID:
30287426
4.

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.

Rambau PF, Vierkant RA, Intermaggio MP, Kelemen LE, Goodman MT, Herpel E, Pharoah PD, Kommoss S, Jimenez-Linan M, Karlan BY, Gentry-Maharaj A, Menon U, Polo SH, Candido Dos Reis FJ, Doherty JA, Gayther SA, Sharma R, Larson MC, Harnett PR, Hatfield E, de Andrade JM, Nelson GS, Steed H, Schildkraut JM, Carney ME, Høgdall E, Whittemore AS, Widschwendter M, Kennedy CJ, Wang F, Wang Q, Wang C, Armasu SM, Daley F, Coulson P, Jones ME, Anglesio MS, Chow C, de Fazio A, García-Closas M, Brucker SY, Cybulski C, Harris HR, Hartkopf AD, Huzarski T, Jensen A, Lubiński J, Oszurek O, Benitez J, Mina F, Staebler A, Taran FA, Pasternak J, Talhouk A, Rossing MA, Hendley J; AOCS Group, Edwards RP, Fereday S, Modugno F, Ness RB, Sieh W, El-Bahrawy MA, Winham SJ, Lester J, Kjaer SK, Gronwald J, Sinn P, Fasching PA, Chang-Claude J, Moysich KB, Bowtell DD, Hernandez BY, Luk H, Behrens S, Shah M, Jung A, Ghatage P, Alsop J, Alsop K, García-Donas J, Thompson PJ, Swerdlow AJ, Karpinskyj C, Cazorla-Jiménez A, García MJ, Deen S, Wilkens LR, Palacios J, Berchuck A, Koziak JM, Brenton JD, Cook LS, Goode EL, Huntsman DG, Ramus SJ, Köbel M.

J Pathol Clin Res. 2018 Oct;4(4):250-261. doi: 10.1002/cjp2.109. Epub 2018 Sep 21.

5.

Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin.

Po JW, Roohullah A, Lynch D, DeFazio A, Harrison M, Harnett PR, Kennedy C, de Souza P, Becker TM.

J Circ Biomark. 2018 Jun 24;7:1849454418782617. doi: 10.1177/1849454418782617. eCollection 2018 Jan-Dec.

6.

Multidisciplinary teams and ICT: a qualitative study exploring the use of technology and its impact on multidisciplinary team meetings.

Janssen A, Robinson T, Brunner M, Harnett P, Museth KE, Shaw T.

BMC Health Serv Res. 2018 Jun 13;18(1):444. doi: 10.1186/s12913-018-3242-3.

7.

Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.

Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, Traficante N; Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DDL, deFazio A.

Gynecol Oncol. 2018 Aug;150(2):239-246. doi: 10.1016/j.ygyno.2018.05.020. Epub 2018 May 26.

PMID:
29807697
8.

Improvement attributes in healthcare: implications for integrated care.

Harnett PJ.

Int J Health Care Qual Assur. 2018 Apr 16;31(3):214-227. doi: 10.1108/IJHCQA-07-2016-0097. Review.

PMID:
29687756
9.

Physiological self-regulation and mindfulness in children with a diagnosis of fetal alcohol spectrum disorder.

Reid N, Harnett P, O'Callaghan F, Shelton D, Wyllie M, Dawe S.

Dev Neurorehabil. 2018 Apr 10:1-6. doi: 10.1080/17518423.2018.1461948. [Epub ahead of print]

PMID:
29634386
10.

Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.

Ring BZ, Murali R, Soslow RA, Bowtell DDL, Fereday S, deFazio A, Traficante N, Kennedy CJ, Brand A, Sharma R, Harnett P, Samimi G; Australian Ovarian Cancer Study.

Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):680-688. doi: 10.1158/1055-9965.EPI-17-1101. Epub 2018 Mar 12.

PMID:
29531130
11.

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, Tołoczko A, Tiezzi DG, Taran FA, Sinn P, Sieh W, Sharma R, Rothstein JH, Ramón Y Cajal T, Paz-Ares L, Oszurek O, Orsulic S, Ness RB, Nelson G, Modugno F, Menkiszak J, McGuire V, McCauley BM, Mack M, Lubiński J, Longacre TA, Li Z, Lester J, Kennedy CJ, Kalli KR, Jung AY, Johnatty SE, Jimenez-Linan M, Jensen A, Intermaggio MP, Hung J, Herpel E, Hernandez BY, Hartkopf AD, Harnett PR, Ghatage P, García-Bueno JM, Gao B, Fereday S, Eilber U, Edwards RP, de Sousa CB, de Andrade JM, Chudecka-Głaz A, Chenevix-Trench G, Cazorla A, Brucker SY; Australian Ovarian Cancer Study Group, Alsop J, Whittemore AS, Steed H, Staebler A, Moysich KB, Menon U, Koziak JM, Kommoss S, Kjaer SK, Kelemen LE, Karlan BY, Huntsman DG, Høgdall E, Gronwald J, Goodman MT, Gilks B, García MJ, Fasching PA, de Fazio A, Deen S, Chang-Claude J, Candido Dos Reis FJ, Campbell IG, Brenton JD, Bowtell DD, Benítez J, Pharoah PDP, Köbel M, Ramus SJ, Goode EL.

Mayo Clin Proc. 2018 Mar;93(3):307-320. doi: 10.1016/j.mayocp.2017.10.023.

12.

Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.

Garsed DW, Alsop K, Fereday S, Emmanuel C, Kennedy CJ, Etemadmoghadam D, Gao B, Gebski V, Garès V, Christie EL, Wouters MCA, Milne K, George J, Patch AM, Li J, Arnau GM, Semple T, Gadipally SR, Chiew YE, Hendley J, Mikeska T, Zapparoli GV, Amarasinghe K, Grimmond SM, Pearson JV, Waddell N, Hung J, Stewart CJR, Sharma R, Allan PE, Rambau PF, McNally O, Mileshkin L, Hamilton A, Ananda S, Grossi M, Cohen PA, Leung YC, Rome RM, Beale P, Blomfield P, Friedlander M, Brand A, Dobrovic A, Köbel M, Harnett P, Nelson BH, Bowtell DDL, deFazio A; Nadia Traficante, for the Australian Ovarian Cancer Study Group.

Clin Cancer Res. 2018 Feb 1;24(3):569-580. doi: 10.1158/1078-0432.CCR-17-1621. Epub 2017 Oct 23.

PMID:
29061645
13.

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Tołoczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf A, Ryan A, Chudecka-Głaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubiński J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Ursula E, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, Anna A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ.

JAMA Oncol. 2017 Dec 1;3(12):e173290. doi: 10.1001/jamaoncol.2017.3290.

14.

Lesson of the month 1: Spontaneous septic thrombophlebitis presenting with bacteraemia diagnosed by PET-CT scan.

Harnett P, Jain S.

Clin Med (Lond). 2017 Oct;17(5):471-472. doi: 10.7861/clinmedicine.17-5-471.

PMID:
28974602
15.

Feasibility randomised multicentre, double-blind, double-dummy controlled trial of anakinra, an interleukin-1 receptor antagonist versus intramuscular methylprednisolone for acute gout attacks in patients with chronic kidney disease (ASGARD): protocol study.

Balasubramaniam G, Parker T, Turner D, Parker M, Scales J, Harnett P, Harrison M, Ahmed K, Bhagat S, Marianayagam T, Pitzalis C, Mallen C, Roddy E, Almond M, Dasgupta B.

BMJ Open. 2017 Sep 5;7(9):e017121. doi: 10.1136/bmjopen-2017-017121.

16.

A biosocial cognitive model of cannabis use in emerging adulthood.

Papinczak ZE, Connor JP, Harnett P, Gullo MJ.

Addict Behav. 2018 Jan;76:229-235. doi: 10.1016/j.addbeh.2017.08.011. Epub 2017 Aug 18.

PMID:
28863315
17.

EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.

Etemadmoghadam D, Azar WJ, Lei Y, Moujaber T, Garsed DW, Kennedy CJ, Fereday S, Mitchell C, Chiew YE, Hendley J, Sharma R, Harnett PR, Li J, Christie EL, Patch AM, George J, Au-Yeung G, Mir Arnau G, Holloway TP, Semple T, Pearson JV, Waddell N, Grimmond SM, Köbel M, Rizos H, Lomakin IB, Bowtell DDL, deFazio A; Australian Ovarian Cancer Study Group.

Cancer Res. 2017 Aug 15;77(16):4268-4278. doi: 10.1158/0008-5472.CAN-16-2224. Epub 2017 Jun 23.

18.

Feasibility study of a family-focused intervention to improve outcomes for children with FASD.

Reid N, Dawe S, Harnett P, Shelton D, Hutton L, O'Callaghan F.

Res Dev Disabil. 2017 Aug;67:34-46. doi: 10.1016/j.ridd.2017.06.004. Epub 2017 Jun 17.

PMID:
28633042
19.

Quality of Caregiving in Mothers With Illicit Substance Use: A Systematic Review and Meta-analysis.

Hatzis D, Dawe S, Harnett P, Barlow J.

Subst Abuse. 2017 Mar 14;11:1178221817694038. doi: 10.1177/1178221817694038. eCollection 2017.

20.

Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study.

Boyd A, Stoodley P, Richards D, Hui R, Harnett P, Vo K, Marwick T, Thomas L.

PLoS One. 2017 Apr 13;12(4):e0175544. doi: 10.1371/journal.pone.0175544. eCollection 2017.

21.

Our Faustian pact with the digital world.

McNeil CM, Harnett PR.

Lancet Oncol. 2017 Feb;18(2):171-172. doi: 10.1016/S1470-2045(17)30005-0. No abstract available.

PMID:
28214405
22.

Severe soft tissue infection masquerading as necrotising fasciitis in a 31-year-old woman with a background of right thigh arteriovenous malformation.

Hever P, Cavale N, Harnett P.

BMJ Case Rep. 2016 Nov 1;2016. pii: bcr2016216951. doi: 10.1136/bcr-2016-216951.

23.

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.

Harbeck N, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, Otremba BJ, Waldenmaier D, Dorn J, Warm M, Scholz M, Untch M, de Wit M, Barinoff J, Lück HJ, Harter P, Augustin D, Harnett P, Beckmann MW, Al-Batran SE; PELICAN Investigators.

Breast Cancer Res Treat. 2017 Jan;161(1):63-72. doi: 10.1007/s10549-016-4033-3. Epub 2016 Oct 31.

24.

An Evidence-Based, Pre-Birth Assessment Pathway for Vulnerable Pregnant Women.

Barlow J, Dawe S, Coe C, Harnett P.

Br J Soc Work. 2016 Jun;46(4):960-973. Epub 2015 Feb 1.

25.

An Online Learning Module to Increase Self-Efficacy and Involvement in Care for Patients With Advanced Lung Cancer: Research Protocol.

Janssen A, Shaw T, Nagrial A, Pene C, Rabbets M, Carlino M, Zachulski C, Phillips J, Birnbaum R, Gandhi T, Harnett P.

JMIR Res Protoc. 2016 Aug 8;5(3):e147. doi: 10.2196/resprot.5547.

26.

Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.

Gao B, Lindemann K, Anderson L, Fereday S, Hung J, Alsop K, Tothill RW, Gebski V, Kennedy C, Balleine RL; Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DD, DeFazio A.

Gynecol Oncol. 2016 Sep;142(3):458-64. doi: 10.1016/j.ygyno.2016.06.023. Epub 2016 Jul 18.

PMID:
27444035
27.

Embedding continuous quality improvement processes in multidisciplinary teams in cancer care: exploring the boundaries between quality and implementation science.

Robinson TE, Janssen A, Harnett P, Museth KE, Provan PJ, Hills DJ, Shaw T.

Aust Health Rev. 2017 Jul;41(3):291-296. doi: 10.1071/AH16052.

PMID:
27372543
28.

Patterns and trends in the incidence of paediatric and adult germ cell tumours in Australia, 1982-2011.

van Leeuwen MT, Gurney H, Turner JJ, Turner SL, Pearson SA, Laaksonen MA, Harnett P, Balakrishnar B, Sabanathan D, Vajdic CM.

Cancer Epidemiol. 2016 Aug;43:15-21. doi: 10.1016/j.canep.2016.05.006. Epub 2016 May 26.

PMID:
27235952
29.

Mindfulness for Motor and Nonmotor Dysfunctions in Parkinson's Disease.

Dissanayaka NN, Idu Jion F, Pachana NA, O'Sullivan JD, Marsh R, Byrne GJ, Harnett P.

Parkinsons Dis. 2016;2016:7109052. doi: 10.1155/2016/7109052. Epub 2016 Apr 10.

30.

The first reported case of Burkholderia contaminans in patients with cystic fibrosis in Ireland: from the Sargasso Sea to Irish Children.

Power RF, Linnane B, Martin R, Power N, Harnett P, Casserly B, O'Connell NH, Dunne CP.

BMC Pulm Med. 2016 Apr 22;16(1):57. doi: 10.1186/s12890-016-0219-z.

31.

A mixed methods approach to developing and evaluating oncology trainee education around minimization of adverse events and improved patient quality and safety.

Janssen A, Shaw T, Bradbury L, Moujaber T, Nørrelykke AM, Zerillo JA, LaCasce A, Co JP, Robinson T, Starr A, Harnett P.

BMC Med Educ. 2016 Mar 12;16:91. doi: 10.1186/s12909-016-0609-1.

32.

Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.

French JD, Johnatty SE, Lu Y, Beesley J, Gao B, Kalimutho M, Henderson MJ, Russell AJ, Kar S, Chen X, Hillman KM, Kaufmann S, Sivakumaran H, O'Reilly M, Wang C, Korbie DJ; Australian Ovarian Cancer Study Group; Australian Ovarian Cancer Study, Lambrechts D, Despierre E, Van Nieuwenhuysen E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching PA, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Pisterer J, Hillemanns P, Nakanishi T, Yatabe Y, Goodman MT, Lurie G, Matsuno RK, Thompson PJ, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan JM, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut JM, Iversen E, Weber RP, Brennan D, Berchuck A, Pharoah P, Harnett P, Norris MD, Haber M, Goode EL, Lee JS, Khanna KK, Meyer KB, Chenevix-Trench G, deFazio A, Edwards SL, MacGregor S; Ovarian Cancer Association Consortium.

Oncotarget. 2016 Feb 9;7(6):6353-68. doi: 10.18632/oncotarget.7047.

33.

Systematic Review of Fetal Alcohol Spectrum Disorder Interventions Across the Life Span.

Reid N, Dawe S, Shelton D, Harnett P, Warner J, Armstrong E, LeGros K, O'Callaghan F.

Alcohol Clin Exp Res. 2015 Dec;39(12):2283-95. doi: 10.1111/acer.12903. Epub 2015 Nov 18. Review.

PMID:
26578111
34.

Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.

Nature. 2015 Nov 19;527(7578):398. doi: 10.1038/nature15716. Epub 2015 Oct 21. No abstract available.

PMID:
26503049
35.

Whole-genome characterization of chemoresistant ovarian cancer.

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.

Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410. Erratum in: Nature. 2015 Nov 19;527(7578):398.

PMID:
26017449
36.

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.

Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Anglesio MS, Sharma R, Russell P, Kennedy C, Fereday S, Hung J, Galletta L, Hogg R, Wain GV, Brand A, Balleine R, MacConaill L, Palescandolo E, Hunter SM, Campbell I, Dobrovic A, Wong SQ, Do H, Clarke CL, Harnett PR, Bowtell DD, deFazio A; Australian Ovarian Cancer Study (AOCS).

Clin Cancer Res. 2014 Dec 15;20(24):6618-30. doi: 10.1158/1078-0432.CCR-14-1292. Epub 2014 Oct 14. Erratum in: Clin Cancer Res. 2016 Aug 15;22(16):4272.

37.

Retrospective imaging audit and cost analysis of medical oncology inpatients admitted to Westmead Hospital.

Gupta S, Taylor N, Selvakumar D, Harnett PR, Wilcken N, Lee CI.

Intern Med J. 2014 Dec;44(12a):1235-9. doi: 10.1111/imj.12565.

PMID:
25169081
38.

ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.

Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J; Australian Ovarian Cancer Study Group, Williams RT, Flemming C, Lambrechts D, Despierre E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching P, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Nakanishi T, Yatabe Y, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan J, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut J, Iversen E, Weber RP, Berchuck A, Goode E, Bowtell DD, Chenevix-Trench G, deFazio A, Norris MD, MacGregor S, Haber M, Henderson MJ.

J Natl Cancer Inst. 2014 Jun 23;106(7). pii: dju149. doi: 10.1093/jnci/dju149. Print 2014 Jul.

39.

Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer.

Gao B, Russell A, Beesley J, Chen XQ, Healey S, Henderson M, Wong M, Emmanuel C, Galletta L, Johnatty SE, Bowtell D; Australian Ovarian Cancer Study Group, Haber M, Norris M, Harnett P, Chenevix-Trench G, Balleine RL, deFazio A.

Sci Rep. 2014 May 9;4:4669. doi: 10.1038/srep04669.

40.

Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels.

Ojaimi S, Harnett PR, Fulcher DA.

J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):105-6. doi: 10.1016/j.jaip.2013.08.009. Epub 2013 Oct 17. No abstract available.

PMID:
24565780
41.

Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis.

Lei Y, Henderson BR, Emmanuel C, Harnett PR, deFazio A.

Oncogene. 2015 Jan 22;34(4):485-95. doi: 10.1038/onc.2013.566. Epub 2014 Feb 17.

PMID:
24531715
42.

Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study.

Fotopoulou C, Vergote I, Mainwaring P, Bidzinski M, Vermorken JB, Ghamande SA, Harnett P, Del Prete SA, Green JA, Spaczynski M, Blagden S, Gore M, Ledermann J, Kaye S, Gabra H.

Ann Oncol. 2014 Jan;25(1):160-5. doi: 10.1093/annonc/mdt515. Epub 2013 Dec 5.

PMID:
24318743
43.

Personality, cognition and hazardous drinking: Support for the 2-Component Approach to Reinforcing Substances Model.

Harnett PH, Lynch SJ, Gullo MJ, Dawe S, Loxton N.

Addict Behav. 2013 Dec;38(12):2945-8. doi: 10.1016/j.addbeh.2013.08.017. Epub 2013 Aug 26.

PMID:
24064194
44.

Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia.

Carus A, Gurney H, Gebski V, Harnett P, Hui R, Kefford R, Wilcken N, Ladekarl M, von der Maase H, Donskov F.

J Transl Med. 2013 Aug 15;11:189. doi: 10.1186/1479-5876-11-189.

45.

Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.

Stoodley PW, Richards DA, Boyd A, Hui R, Harnett PR, Meikle SR, Byth K, Stuart K, Clarke JL, Thomas L.

Eur J Cancer. 2013 Nov;49(16):3396-403. doi: 10.1016/j.ejca.2013.06.046. Epub 2013 Aug 9.

PMID:
23937961
46.

An evaluation of the parents under pressure programme: a study protocol for an RCT into its clinical and cost effectiveness.

Barlow J, Sembi S, Gardner F, Macdonald G, Petrou S, Parsons H, Harnett P, Dawe S.

Trials. 2013 Jul 11;14:210. doi: 10.1186/1745-6215-14-210.

47.

NT-proBNP Changes in Patients with Ascites during Large Volume Paracentesis.

Nguyen V, Zielinski R, Harnett P, Miller K, Chan H, Vootakuru N, Acharya P, Khan M, Gibbs O, Gupta S, Devi A, Phillips S, George J, van der Poorten D.

ISRN Hepatol. 2013 Sep 22;2013:959474. doi: 10.1155/2013/959474. eCollection 2013.

48.

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.

Cowin PA, George J, Fereday S, Loehrer E, Van Loo P, Cullinane C, Etemadmoghadam D, Ftouni S, Galletta L, Anglesio MS, Hendley J, Bowes L, Sheppard KE, Christie EL, Pearson RB, Harnett PR, Heinzelmann-Schwarz V, Friedlander M, McNally O, Quinn M, Campbell P, deFazio A, Bowtell DD; Australian Ovarian Cancer Study.

Cancer Res. 2012 Aug 15;72(16):4060-73.

49.

Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy.

Stoodley PW, Richards DA, Boyd A, Hui R, Harnett PR, Meikle SR, Clarke JL, Thomas L.

Eur Heart J Cardiovasc Imaging. 2013 Mar;14(3):228-34. doi: 10.1093/ehjci/jes139. Epub 2012 Jul 10.

PMID:
22782955
50.

All pains are equal, but some seem more urgent than others.

Harnett P.

Lancet. 2012 Jul 7;380(9836):28. doi: 10.1016/S0140-6736(12)61123-4. No abstract available.

PMID:
22770456

Supplemental Content

Loading ...
Support Center